70 / 1084
3/28/2017
12
Overall survival
3-year survival (95% CI)
CF
39% (35%, 44%)
ECX
42% (37%, 46%)
OE02 CS
31% (27%, 36%)
0.00
0.25
0.50
0.75
1.00
Proportion surviving
400 235 154 120
85
70
50
38
27
OE02CS
446 343 229 172 124
91
70
45
23
ECX
451 345 227 167 121
71
46
21
13
CF
At risk
0 1 2 3 4 5 6 7 8
Time from randomisation (Years)
CF
ECX
OE02CS
Alderson,Cunninghamet al ASCO 2015
Dutch Trial
THO vs TTO
–
TTO
–
More nodes
–
More respiratory complications
–
Lower oesophageal and LN 1-8 better outcome
Survival after TTO vs THO for Type II
Tumours
Survival of ALL Px
Survival
Percent survival
0 365 730 1095 1460 1825 2190 2555 2920 3285 3650
0
25
50
75
100
THO
2-Stage
RMH
MedianSurvival
RMH
54months
THO 49months
2ST
34months
P< 0.0005
SurvivalofTHOvs 2-ST ALLT1-2N0:Survivalproportions
Survival
Percent survival
0 365 730 1095 14601825 2190 2555 2920 3285 3650
0
25
50
75
100
THO
2Stage
SurvivalofTHOvs2-ST ALLT1-2N+:Survivalproportions
Survival
Percent survival
0 365 730 109514601825 21902555 29203285 3650
0
25
50
75
100
THO
2Stage
SurvivalofTHOvs2-ST ALL T3-4N0:Survivalproportions
Survival
Percent survival
0 365 730 1095 1460 1825 2190 2555 2920 3285 3650
0
25
50
75
100
THO
2Stage
SurvivalofTHOvs2-ST ALLT3-4N+:Survivalproportions
Survival
Percent survival
0 365 730 109514601825 21902555 29203285 3650
0
25
50
75
100
THO
2Stage
P= ns
SurvivalofTHOvs2-ST N0:Survivalproportions
Survival
Percent survival
0 365 730 1095 1460 1825 2190 2555 2920 3285 3650
0
25
50
75
100
THON0
2-STN0
SurvivalofTHOvs2-ST ALLN1:Survivalproportions
Survival
Percent survival
0 365 730 1095 1460 1825 2190 2555 2920 3285 3650
0
25
50
75
100
THON1
2-STN1
SurvivalofTHO vs 2-ST ALL N2:Survivalproportions
Survival
Percent survival
0 365 730 1095 1460 1825 2190 2555 2920 3285 3650
0
25
50
75
100
THON2
2-STN2
SurvivalofTHO vs 2-ST ALL N3:Survivalproportions
Survival
Percent survival
0 365 730 1095 1460 1825 2190 2555 2920 3285 3650
0
25
50
75
100
THON3
2-STN3
P= ns